Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7170974 | 1.00 | AAK1 (0.33) | AAK1CHRNB2CHRNA4RAB9A | |
| SCHEMBL7170985 | 1.00 | AAK1 (0.33) | AAK1CHRNB2CHRNA4RAB9A | |
| SCHEMBL7170697 | 1.00 | AAK1 (0.33) | AAK1CHRNB2CHRNA4RAB9A | |
| SCHEMBL7170702 | 1.00 | AAK1 (0.33) | AAK1CHRNB2CHRNA4RAB9A | |
| SCHEMBL7097849 | 0.87 | CHRNB2 (0.36) | AAK1CHRNB2CHRNA4 | |
| SCHEMBL7099305 | 0.86 | AAK1 (0.37) | AAK1 | |
| SCHEMBL3325118 | 0.86 | CHRNB2 (0.49) | CHRNB2CHRNA4RAB9A | |
| SCHEMBL3325125 | 0.86 | CHRNB2 (0.49) | CHRNB2CHRNA4RAB9A | |
| SCHEMBL617955 | 0.85 | AAK1 (0.39) | AAK1CHRNB2CHRNA4RAB9A | |
| SCHEMBL617956 | 0.85 | AAK1 (0.39) | AAK1CHRNB2CHRNA4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | AAK1 3270/4885CHRNB2 9/4885CHRNA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.